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Abstract
Vaccination in alternative settings, defined here as being outside of traditional primary care, can 
help address the pressing public health problem of low human papillomavirus vaccine coverage 
among adolescents in the United States. Pharmacies are promising because they are highly 
accessible and have well established immunization practices. However, pharmacies currently face 
policy and reimbursement challenges. School-located mass vaccination programs are also 
promising because of their high reach and demonstrated success in providing other vaccines, but 
control by local policymakers and challenges in establishing community partnerships complicate 
widespread implementation. Health centers in schools are currently too few to greatly increase 
access to human papillomavirus vaccine. Specialty clinics have experience with vaccination, but 
the older age of their patient populations limits their reach. Future steps to making alternative 
settings a success include expanding their use of statewide vaccine registries and improving their 
coordination with primary care providers.
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Widespread vaccination against HPV could prevent more than two-thirds of cervical cancer 
cases [1] and reduce the incidence of vulvar, vaginal, penile, anal and possibly 
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oropharyngeal cancers, as well as genital warts [2]. As cervical cancer and other HPV-
related cancers disproportionately affect minority, rural and low-income individuals, HPV 
vaccine is particularly important for adolescents in these populations [3]. National 
guidelines recommend routinely providing HPV vaccine to adolescents aged 11–12, with 
catch-up doses for males aged 13–21 and females aged 13–26 [4,5]. For this reason, our 
article focuses on adolescents aged 11–12. Although these guidelines took effect in 2007 for 
females and 2011 for males, HPV vaccination coverage is low and has improved little in 
recent years. By 2012, 33% of girls and 7% of boys aged 13–17 had received the 
recommended three doses [6]. Rates for adolescent girls are largely unchanged from the 
previous year. HPV vaccine coverage is far lower among age-eligible adolescents than 
coverage for other recommended adolescent vaccines, including the combination tetanus, 
diphtheria and pertussis (Tdap) vaccine (85% coverage) and meningococcal conjugate 
vaccine (74% coverage) [6].
Solutions to low vaccine coverage include encouraging healthcare providers to routinely 
offer strong recommendations for HPV vaccine and increasing parent awareness that the 
vaccine is for both adolescent boys and girls. While pediatric and family medicine clinics 
are the primary settings for HPV vaccine administration [7], adolescents visit these settings 
less often than younger children. Most adolescent attend at least one healthcare visit a year, 
but many of these visits are for acute care when vaccination is rarely discussed. Nearly half 
of US children aged 12–17 do not have reliable access to comprehensive primary care [8]. 
Too few primary care providers serve rural and disadvantaged urban areas [9], one reason 
that adolescents from vulnerable groups are less likely to obtain consistent primary care 
[10,11]. The need for multiple visits to complete the HPV vaccine series amplifies these 
problems. Expanding vaccination services to locations outside of traditional settings is one 
way to increase HPV vaccination rates, especially for adolescents with limited access to 
primary care. The US President’s Cancer Panel endorsed alternative vaccination settings as a 
promising way to increase HPV vaccine coverage in the USA [12]. These alternative 
settings can support and fill in gaps in access to primary care.
A CDC working group reviewed several candidate settings outside of pediatrics and family 
medicine for adolescent vaccine administration, including pharmacies, health departments, 
family planning clinics and emergency departments [13]. While the working group 
concluded that these settings were safe and appropriate to provide immunizations to 
adolescents, the group completed their work over 5 years ago, did not consider HPV vaccine 
specifically and did not review potentially relevant settings (e.g., school health centers, mass 
vaccinations programs in schools and dental offices). The aim of this article is to review 
traditional and alternative settings in light of the unique challenges posed by HPV 
vaccination in the USA with particular attention to three considerations: reach or providers’ 
ability to access adolescents aged 11–12, with special emphasis on populations at higher-risk 
for HPV-related cancers later in life; acceptability and convenience of alternative settings 
for adolescents and their parents, healthcare providers and other stakeholders; and feasibility 
of vaccine delivery in terms of storage, availability of healthcare providers trained in 
vaccination, documentation of and remuneration for vaccine doses and policy environment. 
Table 1 summarizes the general findings for each setting.
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Primary care in pediatric & family medicine clinics
Reach—Primary care clinics and practices are the most common setting for prescribing 
adolescent vaccines, usually during visits with pediatricians and family medicine physicians 
[7,14]. Most primary care clinics provide good access to adolescents aged 11–12, though 
access to some populations at higher-risk for HPV-related cancers may be lower [10]. One 
challenge is that, compared with young children, adolescents, particularly boys, make fewer 
preventive care visits in general [14,15], reducing opportunities to provide vaccines and 
increasing patient loss to follow-up. This challenge is exacerbated by most adolescents’ 
healthcare visits being for acute rather than preventive care. Even though adolescents’ less 
frequent contact with pediatric and family medicine clinics may affect immunization 
coverage for all vaccines, HPV vaccination is likely disproportionately impacted given the 
number of visits needed to complete the three-dose series.
Acceptability—Another strength of the primary care setting is that parents 
overwhelmingly indicate that a physician’s clinic is the most desirable setting for HPV 
vaccination, for reasons including familiarity with and trust in their adolescents’ providers 
and ease of tracking vaccinations [16,17]. A barrier to HPV vaccination in primary care 
setting is inconvenience to parents. Additional visits required for series completion 
compound the problems of scheduling visits with a clinic that may offer limited hours, the 
need to travel to a location that may not be close and time spent in the waiting room [18]. 
Some medical practices offer ‘vaccination only’ visits with short wait times to see a nurse, 
but the prevalence of this practice is not well documented.
Healthcare provider recommendation is by far the strongest predictor of HPV vaccine 
uptake [19–25]. However, primary care providers miss most opportunities to recommend the 
vaccine to eligible adolescent patients. Lack of a provider recommendation is one of the 
most common reasons parents of unvaccinated children give for not getting HPV vaccine. 
Furthermore, qualitative research suggests that recommendations that providers do deliver 
for HPV vaccine are often weaker than for other vaccines [26–28]. Although reasons are 
complex, providers’ current practices may be due to discomfort talking about sex with 
adolescents and parents [29].
Another challenge may be physician unfamiliarity or disagreement with the Advisory 
Committee on Immunization Practices (ACIP) guidelines. For instance, primary care 
providers are less likely to recommend HPV vaccine to younger adolescents than older ones, 
despite ACIP recommendations to target patients aged 11–12 [30,31]. Providers may not 
view younger adolescents as being at risk for contracting HPV, and therefore, they may see 
no harm in delaying vaccination [31]. Addressing missed opportunities is an especially 
promising way to increase HPV vaccination coverage.
Feasibility—As primary care settings have a long-standing history of vaccination, the 
feasibility of HPV vaccination in these settings is generally very high. Primary care clinics 
have the personnel and infrastructure to store and deliver vaccine doses safely and 
effectively, and they also typically have insurance billing systems. This primary care-
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centered approach has been successful for Tdap and meningococcal vaccines, demonstrating 
that it is possible to reach the vast majority of adolescents through primary care clinics [28]. 
The CDC estimates that if providers gave HPV vaccine concomitantly with other vaccines 
during an adolescent girl’s health visit, HPV series initiation would be above 90% with 
lower series completion [28]. Even though most adolescents have a medical home and make 
at least one visit yearly [32], providers still miss many opportunities to provide HPV vaccine 
concomitantly with other adolescent vaccines [28,33].
Health department immunization clinics
Reach—Health department immunization clinics are vital safety-net providers of 
immunizations to those who cannot pay or do not have access to a primary care provider 
[13]. Health departments provide the most HPV vaccinations outside of pediatric and family 
medicine clinics, but the absolute number is relatively low [7]. Compared with primary care 
clinics, health departments serve many fewer adolescents, but the patients they serve may be 
more likely to be from populations at higher risk for HPV-related cancers (e.g., minority, 
low income). Furthermore, health departments likely play an essential role for vaccination 
referrals, as smaller or rural primary care clinics and practices may be less likely to stock 
adolescent vaccines, including HPV vaccine, due to cost of storage and inadequate 
reimbursement [34].
Acceptability—Adolescents and parents indicate that a health department immunization 
clinic is an acceptable alternative to a primary care clinic [16,35]. However, many barriers in 
a primary care setting related to convenience are likely also relevant to health departments.
Feasibility—Health department immunization clinics can store and distribute large 
quantities of vaccines [13], and most health departments already stock HPV vaccine [36]. 
However, health departments in different states show substantial variability in the amount of 
vaccine they store and who qualifies to receive it [36]. Some states provide universal 
coverage of vaccines, including HPV vaccine, while other states offer assistance only 
through the Vaccines for Children (VFC) program, which provides ACIP-recommended 
vaccines free of charge for adolescents who are uninsured, underinsured, Medicaid eligible, 
American Indian or Alaska Natives [36,37]. These policies for funding vaccine assistance 
programs affect most settings, but they may be especially pronounced in settings like health 
departments that serve primarily low-income clients. Private insurers may not reimburse for 
office visits and administration fees at health department immunization clinics; such fees 
could be a large barrier for low- and middle-income families.
Promising alternative settings
Pharmacies and schools are the two most promising alternative settings, largely because of 
the exceptional access they provide to adolescents and being acceptable to parents and 
adolescents, though these settings face meaningful challenges to implementing provision of 
HPV vaccine on a national scale.
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Reach—An important advantage of pharmacies is that they have substantial access to 
adolescents. Consumers make an estimated 250 million visits to pharmacies each week [38]. 
In health professional shortage areas and rural areas, pharmacists are the most prevalent 
health-care providers [39] with around 275,000 licensed pharmacists practicing in around 
70,000 pharmacies across the USA [40]. Given their high prevalence in disadvantaged areas, 
pharmacists may have the potential to reach pre-teens and adolescents who otherwise would 
not have regular access to preventive care [13,41]. For instance, a case study from 
Richmond, Virginia showed that one pharmacy chain successfully implemented an 
immunization program that vaccinated around 2500 children and adolescents, of whom 90–
95% were uninsured [42].
Acceptability—Pharmacists are among the most trusted professionals in the USA, along 
with physicians and nurses [43]. The public supports pharmacist-provided immunizations 
for adults, and a growing literature shows that parents and adolescent children also support 
pharmacist provision of vaccines, including HPV vaccine [35,44]. Support is even stronger 
among parents who have adolescent children who have not had a recent visit to their 
healthcare provider [35,44]. In addition, pharmacies are open longer hours than most 
primary care clinics and generally require no appointments [41,45,46]. A study of California 
pharmacies found that adult vaccination at pharmacies was cheaper (lower cost per unit) and 
more likely to be consistent with ACIP guidelines than vaccination in primary care settings 
and mass immunization clinics [47]. It may follow that similar quality of care could be 
provided to adolescents in pharmacies. However, some primary care physicians are not yet 
comfortable with adolescent immunizations in pharmacies, arguing that the availability of 
stand-alone services will lead patients to have fewer primary care visits and receive less 
comprehensive preventive care [48]. To address these concerns, pharmacists who administer 
HPV vaccine must collaborate closely with primary care providers to ensure care 
coordination and build trust [48].
Feasibility—Pharmacists already provide HPV vaccine in the majority of the US states, 
but several challenges exist to more widespread implementation. Many colleges and schools 
of pharmacy place special emphasis on immunization training, enabling a new wave of 
pharmacists to join the workforce as trained immunizers [49]. Given over a decade of 
experience with providing adult immunizations, many pharmacies are equipped and staffed 
to extend such services to adolescents. Pharmacies are unique among the settings we 
reviewed in effectively generating demand for vaccination services through local and 
national advertising campaigns.
A feature of pharmacies that most other traditional and alternative settings lack is the ability 
to bill patients’ insurance while they are at the pharmacy by performing immediate claims 
adjudication. While pharmacies typically do this for medications, they can also process 
claims for many adult vaccines (e.g., herpes zoster, pneumococcal and seasonal influenza). 
Thus, patients find out the cost of vaccination in real time. Although not yet widely tested, it 
may be feasible for pharmacies to conduct claims adjudication for adolescent vaccines. 
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Success of these claims will depend on pharmacists achieving in-network status, which 
anecdotal evidence suggests is uncommon at present.
The largest structural drawback is that insurers often do not confer in-network status to 
pharmacists and pharmacies. Patients often have to pay out of pocket for pharmacy-
delivered vaccination or for administration costs even if they have private health insurance 
that covers the vaccine [41]. Costs for many adolescents receiving vaccines could be 
covered if pharmacists were VFC program providers. Pharmacist vaccination may be 
attractive to private insurers because it does not entail an office visit fee that is common in 
primary care settings.
Another barrier is that, although the number of states allowing adult vaccination at 
pharmacies increased dramatically from 9 in 1995 to all 50 in 2010 [49], many states restrict 
the vaccines pharmacies may offer as well as the age of patients that pharmacists may serve 
[41,48]. Currently, 45 states and US territories allow pharmacists to administer HPV 
vaccine, with 21 states allowing pharmacists to immunize adolescents at least 12 years of 
age with that vaccine [46]. However, the mechanisms by which pharmacists can immunize 
vary substantially by state (e.g., standing orders vs prescription), state laws may constrain 
pharmacists to vaccinating only females and some states do not permit pharmacists to 
vaccinate adolescents younger than age 18 [50]. While efforts to expand pharmacists’ 
immunization authority are underway in several states, medical associations such as the 
American Association of Pediatrics have given only limited support to pharmacies as an 
alternative vaccination setting, endorsing pharmacist provision only if pediatric patients do 
not have reliable access to a primary care clinic [51].
Schools
School health centers
Reach: School health centers (SHCs) are clinics that provide students, and sometimes other 
family members, with comprehensive medical care, including primary care, mental health 
and nutrition counseling services [52]. The over 1900 SHCs that currently operate in the 
USA [52] are in 6% of the nation’s schools [53]. Although not yet widespread, the number 
of SHCs has grown over time, and these clinics have recently benefited from a 4-year, US
$200 million grant in federal funding from the Patient Protection and Affordable Care Act 
(ACA) of 2010 [54]. SHCs are more likely to serve schools with low-income, uninsured and 
minority students. However, many SHCs do not serve schools with adolescents, fewer than 
half of SHCs are located in rural areas, some SHCs are not located on school grounds and 
some states have few or no SHCs [52] limiting their overall reach.
Acceptability: Surveys suggest that parents view SHCs as one of the preferred alternative 
settings because of their convenience and familiarity [16]. Parents do not have to miss work 
to vaccinate their children since students are already attending school daily and using 
services at the health center [55]. Perhaps as a result, adolescents who receive HPV vaccine 
at SHCs are more likely to complete the three-dose series compared with patients vaccinated 
at community clinics [55].
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Feasibility: Most SHCs (85%) are able to provide vaccines [56,57]. In a 2007–2008 
national survey of SHCs, 80% reported offering HPV vaccine [58]. However, a more recent 
North Carolina study found that while 60% of the state’s SHCs had carried the vaccine the 
previous year, only around a quarter still carried it a year later, suggesting some challenges 
to feasibility or demand [59]. Strengths of SHCs include that they have primary care 
providers on staff an average of 31 hours per week [52]. In addition, SHCs are generally 
able to bill private and public third-party payers, and many offer subsidized vaccines 
through the VFC program and State Children’s Health Insurance Plans [58]. Many SHCs are 
already using recommended strategies for tracking vaccinations, such as updating electronic 
health records and contacting primary care providers to inform them of students’ 
immunizations [58]. Evidence shows that such tracking methods help increase immunization 
rates [60]. Challenges include that SHCs are highly heterogeneous with respect to 
administrative systems and policies, many have unstable or variable funding [61], and some 
require a separate vaccine consent in addition to general healthcare consent.
Mass vaccination programs in schools
Reach: Voluntary mass vaccination programs are partnerships between community 
providers (e.g., health departments) and schools, typically without health centers, to 
vaccinate students. These programs can reach most adolescents, since nearly all adolescents 
in the USA attend school [62]. Evidence shows that school vaccination programs have been 
successful both in the USA and abroad in providing vaccines to target populations. The UK 
and regions in Australia and Canada have achieved impressive HPV vaccine coverage of 
adolescent girls through voluntary school programs [63–67]. For example, a recent study in 
Canada found that school programs yielded 75% HPV series completion rate while 
programs in medical clinics achieved only 37% [68]. In the USA, voluntary school-located 
programs have been highly successful in increasing coverage of hepatitis B and flu vaccines 
[69–71], though they have had more limited success for HPV vaccine [61]. While schools 
undoubtedly have the highest reach to adolescents eligible for HPV vaccine, creating mass 
vaccination programs in other non-health-related areas (e.g., churches, sporting events, retail 
outlets) might provide other opportunities to vaccinate boys and girls in the community [72].
Acceptability: Parents [35,73,74], adolescents [35,74] and physicians [56] generally support 
vaccinating at schools. Importantly, parents are more willing to vaccinate at schools if they 
have an adolescent who has not had a recent healthcare visit [44] or regular site for 
healthcare [75], is uninsured [44] or has been previously vaccinated at school [44]. 
Therefore, establishing targeted mass vaccination programs in school districts in which 
adolescents from underserved populations are disproportionately represented may have 
widespread support from the community. The American Association of Pediatrics has 
recommended increasing health providers’ involvement with schools without health centers 
to help adolescent vaccine uptake [56]. Despite support for this approach from many parents 
and healthcare providers, some school leaders such as superintendents and principals may be 
less supportive [76], as they anticipate potential concerns from the many constituents to 
whom they answer. Including school leaders early in the planning process may lessen their 
concerns and improve support for program implementation [76].
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Feasibility: Vaccination programs in schools have to compete with schools’ main priorities 
(educating, transporting and feeding children) [56]. Superintendents and school boards must 
approve the program because local school boards each set their own policies, and the 
vaccination program must also obtain parental consent in advance of vaccinating children, as 
parents are not usually present. Mass vaccination campaigns are often conducted in 
partnership with organizations that can address several additional challenges, such as 
documenting vaccine doses given, reporting them to providers, billing insurance, training 
staff to administer vaccines and maintaining the necessary equipment and facilities [56]. 
Health departments are natural partners for these efforts as their personnel are trained to 
organize large groups of people for disaster and emergency management [77]. State and 
local budget cuts in the USA may reduce funding for school nurses who would then be less 
available to help with mass vaccination programs [78].
Other alternative settings
The remaining alternative settings have limited ability to systematically reach the nation’s 




Reach: Visits by young women to obstetrics-gynecology (OBGYNs) practices increase with 
age. By age 17, more adolescent females visit OBGYNs (33% of seven million visits) than 
pediatricians (23%), and by age 21, over 60% of these visits are to OBGYNs [79]. However, 
these clinics do not see many girls in HPV vaccine’s targeted age range (11–12 years), and 
they do not serve boys. As a result, the role of OBGYNs in HPV vaccination may be mostly 
limited to catch-up efforts among older adolescent girls and young women. However, 
OBGYNs may be able to use routine breast and cervical cancer screening visits with 
adolescents’ mothers to recommend HPV vaccination for their daughters [80]. Women’s 
experiences with cervical health (e.g., treatment for cervical dysplasia) are related to 
intentions to vaccinate their daughters against HPV in some studies [81].
Acceptability: A national survey of HPV vaccine-eligible females, aged 13–26, found that 
89% would get the vaccine if their OBGYNs recommended it [82]. A recent study found 
that OBGYNs were more comfortable vaccinating older females than girls aged 11–12, 
perhaps because younger adolescents are a population these clinicians infrequently serve 
[83]. OBGYNs have been very supportive of HPV vaccination efforts, with strong 
endorsement by the American College of Obstetrics and Gynecology (ACOG) [84]. As 
ACOG recommendations may greatly influence OBGYNs’ decisions to incorporate vaccines 
into their practices, the most recent ACOG endorsement may encourage even more of them 
to provide HPV vaccine.
Feasibility: Among OBGYN practices that administer any immunizations, HPV vaccine is 
the most commonly offered vaccine, and often the only one [85]. Over 90% of OBGYNs 
stock HPV vaccine [83]. However, only 27% of their eligible patients initiate the series, and 
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less than a third of those who initiate go on to receive all three doses [83]. Despite the ability 
to stock and deliver the vaccine, OBGYNs report that barriers to HPV vaccination include 
financial concerns, such as the costs of ordering and storing the vaccine and inadequate 
reimbursement [83] and the belief that vaccines should be provided elsewhere [85–87].
Sexually transmitted infection clinics
Reach: Sexually transmitted infection (STI) clinics are unlikely to see the youngest 
adolescents who are the primary group for HPV vaccination. Males are twice as likely to 
seek care in an STI clinic as females [88]. Moreover, most adolescents who seek care in 
these clinics are already sexually active, increasing the likelihood of previous HPV 
infection. However, they are unlikely to have had all HPV strains that the vaccine protects 
against, and therefore still may benefit from receiving it. A positive however is that STI 
clinics serve a disproportionate number of adolescent from vulnerable US populations that 
are the hardest to reach including poor, uninsured and minority adolescents and young adults 
[13].
Acceptability: As the primary mission of publicly funded STI clinics is to prevent STI 
transmission and sequelae, their providers’ and patients’ interest in HPV vaccination may be 
high. However, few studies have evaluated parents’ and adolescents’ comfort with receiving 
HPV vaccine at STI clinics. Parents may not be as comfortable having their adolescents 
vaccinated in STI clinics given their already low preference for using family planning clinics 
[16] as an alternative setting.
Feasibility: STI clinics face barriers that may make them a less feasible setting for HPV 
vaccine delivery. Only 7 of the 42 STI clinics in the CDC STD Surveillance Network stock 
HPV vaccine, with one of the clinics restricting its administration to females [89]. Clinics 
that wish to administer HPV vaccine in their immunization services may come across 
similar challenges previously seen in hepatitis B vaccinations [89] including cost of the 
vaccine, lack of resources related to vaccine counseling and administration, difficulty 
tracking patients to complete the vaccine series and relatively low uptake [90,91]. In 
addition, although all 50 states have laws allowing minors over age 13 to receive diagnosis 
and treatment of STIs without parental consent, many state laws do not explicitly cover 
prevention in a way that would allow extension to vaccination [92].
Family planning clinics
Reach: Over 3000 Title X and other family planning clinics provide care to the US 
adolescents and adults, largely targeting socioeconomically disadvantaged populations at 
high risk for contracting STIs [13]. Many of these clinics are in rural regions of the country, 
offering care to at-risk and underserved females and males who may not have access to 
routine primary care [13]. However, much as with OBGYN and STI clinics, many patients 
of family planning clinics are already sexually active, making the vaccine likely to be less 
effective in this population.
Acceptability: Currently, little evidence suggests parents and adolescents would seek out 
family planning clinics for HPV vaccine or other adolescent vaccines. Although recognized 
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as a potential setting to expand adolescent immunization [13,16], parents rate family 
planning clinics as one of the least desirable location for their adolescents to receive 
vaccinations as compared with several other sites such as school health and public health 
clinics [16]. Among adolescents themselves, only 35% of 6th grade and 55% of 11th grade 
students found vaccination in a family planning clinics acceptable, the lowest percentage 
among the surveyed alternative settings [93].
Feasibility: Many family planning clinics have experience providing immunizations related 
to STIs such as hepatitis B, providing a tested platform for HPV vaccination [94]. 
Implementing HPV vaccination services may be easier in family planning clinics than in STI 
clinics because of the emphasis on preventive care. To ensure series completion, the vaccine 
series could be timed with routine follow-up visits such as those related to contraception 
refills.
Emergency departments
Reach—Around 5% of the US adolescents, most of whom are uninsured, use emergency 
departments as their only source of healthcare [17,95]. This figure may substantially 
decrease in years to come as more states expand their Medicaid services to the uninsured or 
underserved under the ACA.
Acceptability—Parents and adolescents generally find emergency departments to be an 
acceptable site to get vaccines [14,93], though these studies have not specifically addressed 
HPV vaccine. As preventive healthcare visits are inconsistent with the core practice model 
of providing acute care within emergency departments, emergency department staff 
typically refer patients to primary care providers or public health clinics for such services 
that may also have better access to vaccination histories [96].
Feasibility—Significant obstacles limit the ability of emergency departments to vaccinate 
adolescents, especially in the provision of serial vaccines such as HPV. While the most 
frequently delivered immunization in emergency departments is tetanus (93%) [97] as 
emergency post-exposure prophylaxis for injuries, widespread provision of other vaccines 
within emergency departments may not be cost-effective since reimbursements may be 
lower than the administration costs or insurers may not cover the cost of care at all [13]. 
Some pilot programs have shown that creating an adolescent immunization platform in 
emergency departments is effective in capturing hard-to-reach adolescent populations, 
although such programs have had difficulty demonstrating sustainability [13]. Moreover, 
adolescents generally use emergency department services for acute care, making it difficult 
to ensure that patients who start the multi-dose HPV series complete it.
Dental practices
Reach—Around 80% of children and adolescents have had a dental visit within the past 12 
months [98]. While racial and ethnic disparities in dental visits have been significant in the 
past, recent data show that such differences have been attenuated substantially [98]. The 
high access to adolescents may make dental practices worth considering as a setting for 
HPV vaccine provision.
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Acceptability—Though the link between HPV and oral cancer provides a rationale for 
involving dentists, parents’ and adolescents’ comfort with receiving HPV vaccination in a 
dental office is not known. Dentists and dental hygienists are becoming more aware of the 
link between HPV infection and oral cancer, but they have a wide variation in knowledge 
and attitudes surrounding HPV-associated oral cancer, HPV vaccine and the role of the 
provider in counseling and raising awareness about such topics [99].
Feasibility—With no precedent for vaccination or infrastructure to support it in terms of 
vaccine refrigeration, training to deliver doses and status as in-network providers, 
administration of HPV vaccine is not currently feasible in most dental offices. Although 
dentists are trained in medical procedures involving injections, they are not trained to 
administer vaccines or to monitor for related side effects. The rapidly increasing rate of 
oropharyngeal cancer may create new interest among dentists to expand beyond the current 
sporadically adopted practice of oral cancer screening. Additional research on revising 
dental practice and developing policies to help standardize these practices could help 
dentists play a more central role in HPV vaccination in the future.
Expert commentary
Dr Tom Frieden, the Director of the CDC, stated in 2013 that progress in HPV vaccination 
had stalled, a failure of providing the vaccine primarily through traditional primary care 
settings [100]. Reaching the nation’s goal of widespread HPV vaccination will require 
interventions in traditional settings, but these interventions should be paired with efforts in 
alternative settings. Use of pharmacies and mass vaccination efforts in schools are among 
the most promising strategies because of their high reach, good acceptability and potential 
for feasible implementation. Other alternative settings in specialty practices (OBGYN, STI 
and family planning), emergency departments and dental offices were less promising.
A key challenge of alternative settings is creating demand for their vaccination services 
among parents and adolescents. To some extent, comfort with these alternative settings will 
increase over time as settings like pharmacies become more common locations for adult 
vaccination and other services. Promotion of vaccination services by settings like 
pharmacies will also help. Other settings like schools may benefit from evidence-based tools 
for boosting parent and adolescent interest in and consent to vaccination, especially in the 
absence of effective school entry requirements for HPV vaccination. Such requirements for 
Tdap and meningococcal vaccines have substantially increased adolescent vaccine coverage 
in the USA [101], but similar requirements for HPV vaccine have been unpopular [102,103] 
and not very effective [104]. No-cost, voluntary mass vaccination programs have been well 
received and as a result achieved high immunization rates in other countries [104]. State 
vaccination registries have reminder-recall functions that can increase immunization in 
adolescents [105]. Though primary care settings have largely failed to routinely use this 
effective intervention, adoption of such systems by alternative settings more accustomed to 
promotion could increase demand for HPV vaccine.
Alternative settings’ ability to adequately document vaccine doses and to communicate with 
adolescents’ primary care providers is of concern to parents and physicians [44,56,74]. 
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Large chain pharmacies have record systems that are interoperable that allow any 
pharmacist within that network to access a patient’s profile to verify the vaccination records. 
However, systems are not interoperable between different chains or independent 
pharmacies, and in many states, pharmacy practice laws do not require pharmacies to report 
administered vaccines back to patients’ primary care providers or state immunization 
registries. Moreover, some pharmacists and providers in other alternative settings must rely 
on patient-reported vaccination history, because they do not yet have access to state vaccine 
registries or patients’ medical records. Fostering coordinated care will require addressing the 
limited or lack of access to registries and medical records, along with establishing a 
standardized way for alternative settings to report vaccine doses to primary care providers. 
Mass vaccinations in schools that do not have electronic record keeping meet substantial 
challenges in reporting. By using state immunization registries and reporting vaccination to 
primary care providers, alternative HPV vaccine providers could address this barrier, as well 
as track vaccine delivery to ensure compliance.
The ability of alternative settings to bill private insurance will determine their long-term 
viability as HPV vaccine providers. Private insurance coverage for HPV vaccine currently 
varies widely by plan [37,106]. As the provisions of the ACA take effect, plans will provide 
first dollar coverage for ACIP-recommended vaccines, including HPV vaccine [106], but 
this will not establish alternative settings as in-network providers. Creating in-network status 
for pharmacists and school-located programs can go a long way in reducing the financial 
burden for both patients and providers, and will promote an environment that would allow 
adolescents and their parents the flexibility to choose where they receive their preventive 
care.
The federally funded VFC program that funds ACIP-recommended vaccines free of charge 
for eligible adolescents is central to vaccine provision in the USA, but many alternative 
settings may not yet have access to this program. Some states, such as Nevada, have readily 
available application forms and guidelines to help pharmacies enroll in and deliver vaccines 
through the VFC program [107], and the CDC offers continuing education to healthcare 
providers, including pharmacists, to learn about this program [108]. Pharmacies or other 
alternative settings choosing not to become VFC providers would substantially limit their 
reach.
While pharmacies and schools are the most promising alternative settings for HPV 
vaccination, other alternative settings may play a small role in providing the vaccine. Most 
OBGYN practices already provide HPV vaccine, but they miss the opportunity to vaccinate 
the majority of their patients, and their reach to adolescents is limited. Specialty practices 
like STI and family planning clinics, constrained by federal and state funding, may struggle 
to expand HPV immunization programs effectively despite their past experiences with 
vaccination services. Continued financial and legislative support for these clinics that deliver 
HPV vaccine may help provide a safety net for patients who are socioeconomically 
disadvantaged, but will never have as meaningful of a reach as primary care clinics, 
pharmacies or mass vaccination in schools. Additionally, family planning and STI clinics 
are not preferred vaccination sites among parents, making these clinics less promising 
alternative settings as compared with pharmacies and schools. Also, issues surrounding 
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scope of practice in some of these alternative settings pose large barriers. Emergency 
departments and dental clinics are not presently viable as alternative settings for delivering 
HPV vaccine.
Five-year view
Lost opportunities to vaccinate this generation of adolescents will result in needless HPV-
related disease burden in the USA in the years to come. An estimated 53,000 cases of HPV-
related cancers could potentially be prevented in the future if 80% of today’s US adolescents 
aged 11–12 completed the HPV series [28]. The lost opportunity will be even larger once 
the FDA approves a new nonavalent HPV vaccine that may prevent almost all cervical 
cancers and the majority of high-grade pre-cancers [109]. While improving HPV vaccine 
provision in primary care will be an important area of intervention, increasing use of 
alternative vaccination settings can help offset some of the burden on our nation’s primary 
care providers, and provide more opportunities to vaccinate the US adolescents.
We can address some of the challenges to HPV vaccine delivery in alternative settings by 
using already identified best practices. Future research and program implementation with 
pharmacy provision of HPV vaccine should explore collaborative practice models with 
primary care providers. Collaborative practice agreements allow physicians to extend their 
capacity for patient care by having patients receive some preventive services such as HPV 
vaccination at a local pharmacy. One possibility to address physician organizations’ 
concerns about pharmacists-provided HPV vaccination is for a primary care provider to 
administer the initial vaccine dose, and then allow community pharmacists to complete the 
series [48]. This referral method could ease the burden on parents for scheduling multiple 
additional primary care visits by providing better hours, more convenient locations and 
possibly lowering costs, while providing similar quality of care as primary care clinics.
Future iterations of mass vaccination programs in schools could take several approaches to 
be more successful. First, schools can form community partnerships with health 
departments, community clinics and pharmacies to furnish the vaccine to their students [77]. 
Strategies to accomplish this goal include harnessing the existing capacity of local health 
departments to organize large-scale health interventions [77]. Second, school-located 
programs should focus on adolescent vaccines, not just HPV vaccine, to minimize reactance 
[59]. Third, these programs should be hosted at the schools and not offsite to improve 
participation [76]. Fourth, best practices to improve consent procedures may increase 
participation among adolescents and their parents. For example, schools can: offer 
incentives to individual children or peer groups for returning forms that indicate whether 
parents give consent; design consent forms that are simple, using visual clues to identify 
where parents should sign and are printed in all relevant languages [110]; and use forms that 
allow parents the option to approve all vaccines, rather than each vaccine individually [111]. 
Importantly, schools offering vaccines have been more successful when providing vaccine-
related information through multiple mechanisms such as teacher-led student assemblies 
[112] and dedicated websites for vaccine information [67]. Finally, best practices and 
recommendations also exist for the physical layout of the vaccination setting [113] and the 
preparation and flow of students through the vaccine delivery area [112].
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Among the many potential alternative settings, we believe that pharmacies and schools have 
the largest potential for increasing HPV vaccine coverage (Table 1). These settings offer 
high reach, convenience and a history of successful immunization in and outside of the 
USA. While many pharmacies and schools do not yet have the capacity to pursue strategies 
that we outline in our paper (e.g., expanding insurance coverage or collaborative practice 
models in pharmacies), such strategies provide future directions that researchers and 
policymakers can take to test the feasibility of providing HPV vaccine in these settings.
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• Human papillomavirus (HPV) vaccine coverage among adolescents remains low 
as initial increases in coverage have stagnated, despite national 
recommendations.
• Causes of low HPV vaccination include missed opportunities in traditional 
primary care settings to vaccinate and inadequate primary care provider 
recommendations to adolescents and their parents.
• Pharmacies and voluntary mass vaccination programs in schools are already 
effectively providing vaccines in the USA.
• The most promising alternative settings are pharmacies and voluntary mass 
vaccination programs in schools, in part because they have the greatest potential 
reach to adolescents aged 11–12.
• Specialty clinics are less promising alternative sites as they have more limited 
access to adolescents, have low acceptability as providers of HPV vaccine or 
face substantial challenges to feasibility.
• Emergency departments and dental practices do not prioritize HPV vaccination 
because of scope of practice and may not play a large role in HPV vaccine 
provision without revision to practice.
• Expanding access to immunization registries, developing reimbursement 
mechanisms and maximizing care coordination will help make alternative 
settings more acceptable and sustainable for HPV vaccination.
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